Molomics is a small molecule drug discovery company. Our fundamental approach integrates Artificial Intelligence (AI) with Human Collective Intelligence (HCI) in a technology to determine novel chemical structures with high therapeutic activity and superior pharmacological properties as currently developed or marketed drugs. Molomics first project is a drug for Levadopa Induced Dyskinesia, a movement disorder which affects Parkinson patients.